Measuring glycaemic variation

Current Diabetes Reviews

Volumn 6, Issue 1, 2010, Pages 17-26

  Cameron, Fergus J ^a   Donath, Susan M ^b   Baghurst, Peter A ^c,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c North Adelaide SA   (United States)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Comparison; Glycaemic variation; Measurement

Indexed keywords

GLUCOSE;

ALGORITHM; BLOOD GLUCOSE MONITORING; CORRELATION COEFFICIENT; DATA BASE; DIABETES MELLITUS; FLUCTUATING ASYMMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT;

BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; KINETICS; MONITORING, AMBULATORY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 77950843251     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339910790442592     Document Type: Review

References (47)

1. Bolli GB. Glucose variability and its complications. Diabetes Care 2006; 29: 1707-1709
2. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood sugar control in diabetes mellitus. Arch Med Scand 1965; 177: 95-102.
3. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19: 644-655
4. Service FJ, Nelson RL. Characteristics of glycaemic stability. Diabetes Care 1980; 3: 58-62.
5. Wójcicki JM. "J"-index: a new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 1995; 27: 41-42
6. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005; 7: 253-263
7. Kovatchev BP, Straume M, Cox DJ, Farhy LS. Risk analysis of blood glucose data: a quantitative approach to optimizing the control of insulin dependent diabetes. J Theor Med 2001; 3: 1-10. (Pubitemid 34498507)
8. Kovatchev BP, Cox DJ, Gonder-Frederick L, Clarke WL. Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabetes Technol Ther 2002; 4: 295-303. (Pubitemid 34666277)
9. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006; 29: 2433-2438 (Pubitemid 44912248)
10. Kessler L, Passemard R, Oberholzer J, et al. GRAGIL Group. Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: interest of continuous glucose monitoring. Diabetes Care 2002; 25: 2256-2262 (Pubitemid 41071037)
11. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004; 53: 955-962 (Pubitemid 38436607)
12. Hill NR, Hindmarsh PC, Stevens RJ, Stratton IM, Levy JC, Matthews DR. A method for assessing quality of control from glucose profiles. Diabet Med 2007; 24: 753-758 (Pubitemid 47012121)
13. No authors listed. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983
14. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005; 19: 178-181 (Pubitemid 40615551)
15. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7. (Pubitemid 40105088)
16. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care 2008; 31: S150-4.
17. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003; 52: 2795-2804 (Pubitemid 37339710)
18. Giannini S, Benvenuti S, Luciani P, et al. Intermittent high glucose concentrations reduce neuronal precursor survival by altering the IGF system: the involvement of the neuroprotective factor DHCR24 (Seladin-1). J Endocrinol 2008; 198: 523-532
19. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 16817.
20. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006; 295: 1681-1687
21. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29: 1486-1490 (Pubitemid 44127568)
22. Kilpatrick ES, Rigby AS, Atkin SL. A1c variability and the risk of microvascular complications in type 1 diabetes: data from the diabetes control and complications trial. Diabetes Care 2008; 31: 2198-2202
23. Pickup JC, Kidd J, Burmiston S, Yemane N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 2006; 22: 232-237 (Pubitemid 43805405)
24. Kohnert KD, Augstein P, Heinke P, et al. Chronic hyperglycemia but not glucose variability determines HbA1c levels in wellcontrolled patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 77: 420-426 (Pubitemid 47211341)
25. Bloomgarden ZT. Type 1 diabetes and glucose monitoring. Diabetes Care 2007; 30: 2965-2971
26. Bragd J, Adamson U, Backlund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008; 34: 612-616
27. Bischof F, Meyerhoff C, Pfeiffer EF. Quality control of intensified insulin therapy: HbA1c versus blood glucose. Horm Metab Res 1994; 26: 574-578 (Pubitemid 24381115)
28. Oyibo SO, Prasad YDM, Jackson NJ, Jude EB, Boulton AJM. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002; 19: 870-873
29. Wojcicki JM. Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull "M"-value. Horm Metab Res 1995; 27: 1-5.
30. Monnier L, Colette C, Boegner C, Pham TC, Lapinski H, Boniface H. Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom? Diabetes Metab 2007; 33: 247-252
31. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care 1997; 20: 1655-1658 (Pubitemid 27463037)
32. Yoshioka K, Azukari K, Ashida K, et al. The efficacy of voglibose on daily glycemic excursions assessed by the "J"-index in non-insulin dependent diabetes mellitus. Horm Metab Res 1997; 29: 407-408 (Pubitemid 27362067)
33. Wójcicki JM, Ladyzynski P, Krzymien J, et al. What we can really expect from telemedicine in intensive diabetes treatment: results from 3-year study on type 1 pregnant diabetic women. Diabetes Technol Ther 2001; 3: 581-589 (Pubitemid 34202916)
34. Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006; 73: 277-284 (Pubitemid 44663094)
35. Ladyzynski P, Wojcicki JM, Krzymien J, et al. Mobile telecare system for intensive insulin treatment and patient education: first applications for newly diagnosed type 1 diabetic patients. Int J Artif Organs 2006; 29: 1074-1081 (Pubitemid 46029286)
36. Ismail D, Gebert R, Vuillermin PJ, et al. Social consumption of alcohol in adolescents with Type 1 diabetes is associated with increased glucose lability, but not hypoglycaemia. Diabet Med 2006; 23: 830-833 (Pubitemid 44141069)
37. Praet SF, Manders RJ, Meex RC, et al. Glycaemic instability is an underestimated problem in type II diabetes. Clin Sci 2006; 111: 119-126 (Pubitemid 44220525)
38. Wentholt IME, Kulik W, Michels RPJ, Hoekstra JBL, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008; 51: 183-190 (Pubitemid 50002199)
39. Zaccardi F, Pitocco D, Ghirlanda G. Glycaemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab Res Rev 2009; 25: 199-207.
40. Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther 2005; 7: 849-862 (Pubitemid 43133992)
41. McCall AL, Cox DJ, Crean J, Gloster M, Kovatchev BP. A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther 2006; 8: 644-653 (Pubitemid 44871494)
42. Kovatchev BP, Crean J, McCall A. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. Diabetes Technol Ther 2008; 10: 391-396
43. Ryan EA, Shapiro AJ. A patient with severe, recurrent hypoglycemia and glycemic lability who underwent islet transplantation. Nat Clin Pract Endocrinol Metab 2006; 2: 349-353
44. Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care 2007; 30: 1370-1373 (Pubitemid 46871140)
45. Bruttomesso D, Crazzolara D, Maran A, et al. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med 2008; 25: 326-332 (Pubitemid 351322703)
46. White NH, Chase HP, Arslanian S, Tamborlane WV. A comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes. Diabetes Care 2009; 32: 387-393
47. Bugler J. An estimation of the amount of data required to measure glycaemic variability. 1st International conference on Advanced Technologies and Treatments for Diabetes, Prague, Czech Republic, February 27-March 1, 2008; p55. Abstract # 46.